Andere Sprachen Compass Therapeutics, Inc.

Aktien

A2QF3P

US20454B1044

CMPX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
1.65 ^USD	+5.10%		+11.49%	+5.77%

25.04.	Compass Therapeutics erhält FDA-Fast-Track-Zulassung für Behandlung von Gallengangskrebs	MT
25.04.	Compass Therapeutics, Inc. erhält FDA Fast Track Designation für die Untersuchung von CTX-009 in Kombination mit Paclitaxel zur Behandlung von Patienten mit metastasierten oder lokal fortgeschrittenen Gallenwegstumoren, die bereits zuvor behandelt worden sind	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment	25.04.
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment	25.04.
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated	25.04.
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated	25.04.
Compass Therapeutics : 2024 Proxy	24.04.
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data	17.04.
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers	16.04.
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors	16.04.
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors	16.04.
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference	15.04.
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference	12.04.
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days	10.04.
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting	09.04.
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update	21.03.
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	29.02.
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial	28.02.
Compass Therapeutics Reports Positive Result in Lung Cancer Treatment Trial -- Shares Rise	05.01.
Compass Therapeutics Provides Corporate Update	05.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Compass Therapeutics, Inc.

Aktien

A2QF3P

US20454B1044

CMPX

Andere Sprachen

Filter